Your browser is no longer supported. Please, upgrade your browser.
Settings
BLUE bluebird bio, Inc. daily Stock Chart
BLUE [NASD]
bluebird bio, Inc.
Index- P/E- EPS (ttm)-6.00 Insider Own0.70% Shs Outstand49.92M Perf Week6.27%
Market Cap9.02B Forward P/E- EPS next Y-9.27 Insider Trans-30.22% Shs Float49.87M Perf Month-3.99%
Income-276.10M PEG- EPS next Q-2.37 Inst Own- Short Float7.85% Perf Quarter4.36%
Sales44.60M P/S202.15 EPS this Y25.40% Inst Trans0.08% Short Ratio4.78 Perf Half Y5.21%
Book/sh31.45 P/B5.74 EPS next Y1.70% ROA-23.00% Target Price219.72 Perf Year88.13%
Cash/sh22.46 P/C8.04 EPS next 5Y- ROE-27.60% 52W Range85.65 - 236.17 Perf YTD1.40%
Dividend- P/FCF- EPS past 5Y17.50% ROI-12.70% 52W High-23.53% Beta2.10
Dividend %- Quick Ratio10.80 Sales past 5Y153.30% Gross Margin- 52W Low110.86% ATR7.90
Employees518 Current Ratio10.80 Sales Q/Q135.30% Oper. Margin- RSI (14)57.61 Volatility3.24% 5.44%
OptionableYes Debt/Eq0.10 EPS Q/Q-37.10% Profit Margin- Rel Volume0.60 Prev Close180.30
ShortableYes LT Debt/Eq0.10 EarningsAug 01 AMC Payout- Avg Volume819.30K Price180.60
Recom2.10 SMA205.79% SMA501.78% SMA2003.20% Volume491,560 Change0.17%
Jul-12-18Initiated Gabelli & Co Buy $239
Jun-19-18Upgrade Evercore ISI In-line → Outperform
Mar-21-18Reiterated Morgan Stanley Equal-Weight $152 → $209
Mar-14-18Initiated Janney Neutral
Mar-05-18Initiated William Blair Outperform
Feb-22-18Reiterated Cantor Fitzgerald Underweight $122 → $113
Jan-25-18Downgrade Leerink Partners Outperform → Mkt Perform
Dec-21-17Initiated Oppenheimer Perform
Dec-13-17Reiterated Barclays Overweight $162 → $209
Dec-13-17Downgrade Maxim Group Buy → Hold $200
Dec-11-17Upgrade Jefferies Hold → Buy $130 → $211
Dec-11-17Reiterated Goldman Buy $186 → $309
Dec-11-17Reiterated Cantor Fitzgerald Underweight $58 → $113
Dec-05-17Initiated Canaccord Genuity Buy $202
Nov-30-17Reiterated Maxim Group Buy $170 → $200
Nov-06-17Downgrade Evercore ISI Outperform → In-line
Nov-03-17Upgrade Morgan Stanley Underweight → Equal-Weight
Nov-02-17Upgrade BTIG Research Neutral → Buy $177
Oct-16-17Upgrade Evercore ISI In-line → Outperform
Oct-11-17Resumed Jefferies Hold $126
Jul-08-18 03:15PM  Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far Motley Fool
Jul-06-18 08:20AM  Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio ACCESSWIRE
Jun-30-18 07:16AM  Celgene Investors Breathe a Sigh of Relief After Acceleron's Success Motley Fool
Jun-28-18 07:40AM  Analysis: Positioning to Benefit within EMCOR Group, Ring Energy, A. O. Smith, bluebird bio, Ligand Pharmaceuticals, and Synovus Financial Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-27-18 06:11PM  Why Sangamo Therapeutics and bluebird bio Slipped Lower Today Motley Fool
Jun-25-18 08:05AM  Today's Research Reports on Stocks to Watch: bluebird and Ampio Pharmaceuticals ACCESSWIRE -5.15%
Jun-23-18 10:21AM  Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives Benzinga
Jun-21-18 08:25AM  Today's Research Reports on Trending Tickers: bluebird bio and Exelixis ACCESSWIRE
Jun-19-18 07:30AM  Blog Exposure - bluebird bio Announces Encouraging New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin(TM) Gene Therapy in Patients with Transfusion-Dependent -Thalassemia ACCESSWIRE
07:00AM  Free Technical Research on BioPharmX and Three More Biotech Equities bio ACCESSWIRE
Jun-15-18 08:20AM  Today's Research Reports on Trending Tickers: Puma Biotechnology and bluebird bio ACCESSWIRE -7.06%
06:00AM  bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent -Thalassemia at Annual Congress of the European Hematology Association Business Wire
06:00AM  Bluebird Bio Gene Therapies Show Promise Against Deadly Anemias Forbes
06:00AM  bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association Business Wire
Jun-13-18 02:55PM  Hematology Conference Could Spur Some of Biotech's Outperformers Bloomberg
Jun-05-18 08:20AM  Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio ACCESSWIRE
08:00AM  bluebird bio Announces Investor Events in June Business Wire
Jun-04-18 05:09PM  Bluebird Bio's Multiple Myeloma Data Reinforces Canaccord Genuity's Bullish Thesis Benzinga
04:16PM  Could Celgene Shake Up the CAR-T Market? Motley Fool
09:38AM  Bluebird Bio shares lift 9% on CAR-T cancer therapy results MarketWatch
Jun-03-18 02:10PM  #ASCO18: A Weekend of Surprises Motley Fool
Jun-01-18 09:22PM  Is bluebird bio Inc (NASDAQ:BLUE) Worth $182.8 Based On Intrinsic Value? Simply Wall St.
06:13PM  Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet Forbes
05:57PM  Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Business Wire
May-30-18 07:40AM  Something Borrowed, Something Blue, Volume 2: It's Been a Roller-Coaster Ride for BLUE Shareholders Motley Fool
07:02AM  Something Old, Something New, Something Borrowed, Volume 2: A Particularly Motley Podcast Motley Fool
May-24-18 06:31AM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio Motley Fool
May-23-18 08:00AM  FDA Grants Breakthrough Therapy Designation to Lenti-D for the Treatment of Cerebral Adrenoleukodystrophy Business Wire
May-17-18 12:27PM  Is bluebird bio Incs (NASDAQ:BLUE) Liquidity Good Enough? Simply Wall St. +6.11%
09:00AM  bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent -Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association Business Wire
May-16-18 05:00PM  bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Business Wire
May-15-18 08:30AM  Investor Expectations to Drive Momentum within Aerohive Networks, M/I Homes, bluebird bio, Penske Automotive Group, Sanmina, and Genesco Discovering Underlying Factors of Influence GlobeNewswire
May-14-18 08:00AM  Today's Research Reports on Trending Tickers: Omeros and bluebird bio ACCESSWIRE
03:49AM  Medigene in for up to $1.5 bln under broader pact with Bluebird Bio Reuters
May-12-18 07:16AM  Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc. Motley Fool
May-09-18 04:55PM  bluebird bio Looks for Data Ahead Motley Fool
May-08-18 08:00AM  bluebird bio to Present at Investor Conferences in May Business Wire
May-07-18 11:31AM  bluebird bio Inc (NASDAQ:BLUE) Is Expected To Breakeven Simply Wall St.
May-02-18 07:25PM  Bluebird: 1Q Earnings Snapshot Associated Press
04:10PM  bluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progress Business Wire
May-01-18 10:42AM  bluebird bio Inc (NASDAQ:BLUE): Does The Earnings Decline Make It An Underperformer? Simply Wall St.
Apr-22-18 07:15AM  2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line Motley Fool
Apr-20-18 10:01AM  A Winning Stock Picker's 8 Favorite Plays Investopedia
06:30AM  Is bluebird bio One Step Closer to Its First Commercial Drug? Motley Fool
Apr-19-18 12:00AM  Gene Therapy Shows Promise in Patients with a Blood Disorder The Wall Street Journal
Apr-18-18 05:00PM  Gene Therapy Shows Promise in Patients with a Blood Disorder The Wall Street Journal
05:00PM  bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent -Thalassemia Business Wire
Apr-16-18 08:00AM  bluebird bio to Present at Alliance for Regenerative Medicines 6th Annual Cell & Gene Therapy Investor Day Business Wire
Apr-15-18 01:17PM  Is bluebird bio, Inc. a Buy on the Dip? Motley Fool
Apr-05-18 01:00PM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio Motley Fool
08:20AM  Todays Research Reports on Trending Tickers: Conatus Pharmaceuticals and bluebird bio ACCESSWIRE
06:00AM  4 Biotechs Ready for Big Rebounds Investopedia
Apr-04-18 09:15PM  3 Top Biotech Stocks to Buy in April Motley Fool +7.88%
Mar-29-18 11:00AM  Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate Zacks
Mar-28-18 01:09PM  Celgene Shares Higher on Co-Development Pact With Bluebird TheStreet.com
08:00AM  bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States Business Wire
Mar-21-18 09:00AM  This Is My Favorite Biotech Stock To Buy On Sale Motley Fool
Mar-14-18 09:53AM  Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued Benzinga
Mar-13-18 07:57AM  Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics Zacks
Mar-12-18 08:40AM  Blog Exposure - InflaRx Enrolled First Patient in Phase-IIb Trial of Lead Candidate IFX-1 in Hidradenitis Suppurativa ACCESSWIRE
Mar-11-18 10:31PM  bluebird bio Inc (BLUE), Iqvia Holdings Inc (IQV): Four Biotech Stocks to Buy Now Insider Monkey
Mar-07-18 08:00AM  bluebird bio to Present at Investor Conferences in March Business Wire
Mar-05-18 02:44PM  William Blair: Bluebird Bio Could See Another 'Blue Ribbon Year' In 2018 Benzinga
Feb-27-18 11:30PM  Why Oppenheimer Global fund is focusing on biotech as rates rise Reuters
Feb-26-18 08:12AM  Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio Zacks
Feb-23-18 07:09PM  3 Big Drugmakers Boosting Huge R&D Budgets Motley Fool
Feb-22-18 06:07PM  bluebird bio Updates Plans for the Year Ahead Motley Fool
Feb-21-18 05:51PM  Bluebird reports 4Q loss Associated Press
04:05PM  bluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress Business Wire
Feb-17-18 10:31AM  How Celgene Hopes to Cash In on CAR-T Motley Fool
Feb-14-18 08:00AM  bluebird bio Appoints Alison Finger as Chief Commercial Officer Business Wire
Feb-06-18 05:10PM  Here's Why bluebird bio Soared 15% in January Motley Fool
Feb-05-18 12:39PM  Here's Why Global Blood Therapeutics Inc. Soared 47.1% in January Motley Fool
Feb-02-18 08:00AM  bluebird bio to Present at LEERINK Partners Global Healthcare Conference Business Wire
Jan-31-18 07:40AM  Recent Analysis Shows Forward Industries, Sigma Designs, Northeast, bluebird bio, Walker & Dunlop, and Atmos Energy Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jan-30-18 02:35PM  Celgene Looking Good With Plans for More Growth Motley Fool
Jan-26-18 10:53AM  Analysts Take Action on Abbott and Bluebird Bio GuruFocus.com
10:30AM  5 Biotechs That May Surge On Takeovers Investopedia
Jan-25-18 10:24AM  Leerink: Bluebird Bio's Catalysts Are Priced In Benzinga
Jan-24-18 02:35PM  Behind Celgenes Strategy in the Juno Therapeutics Acquisition Market Realist
Jan-23-18 09:39AM  Bluebird Up on Buyout Speculation After Celgene/Juno Deal Zacks
08:00AM  Celgene's Investments Are Soaring Motley Fool
07:31AM  These 3 Stocks Have Doubled Investors' Money Motley Fool
Jan-22-18 02:05PM  Why bluebird bio Is Soaring 11.9% Today Motley Fool +10.63%
02:00PM  Bluebird Bio Shouldn't Be Blue Bloomberg
11:23AM  Biotech M&A takes off as Sanofi and Celgene spend $20 billion Reuters
Jan-17-18 07:30AM  Could Little Known Orgenesis (ORGS) Become A Dominant Player in The Multi Billion Dollar Cell Therapy Market? ACCESSWIRE +7.28%
Jan-14-18 09:00AM  5 Biotech Stocks That Could Be Bought Out in 2018 Motley Fool
Jan-11-18 07:31PM  What bluebird bio Wants You to Know About Its Business Motley Fool
08:00AM  Up 188.7%, Is bluebird bio. Stock Still a Strong Buy? Motley Fool
Jan-08-18 04:05PM  bluebird bio Announces Closing of Over-Allotment Option in Public Offering Business Wire
Jan-02-18 04:22PM  Here's How bluebird bio, Inc. Crushed It in 2017 Motley Fool
Dec-28-17 11:46AM  2018 Should Be Better for Celgene Corporation and CELG Stock InvestorPlace
Dec-21-17 04:15PM  bluebird bio to Present at Investor Conferences in January Business Wire
Dec-20-17 06:32AM  What to Expect From Celgene Corporation in 2018 Motley Fool
Dec-19-17 11:02AM  Celgene Stock Up Huge On Exciting CAR-T News Motley Fool
11:02AM  Celgene Shareholders Excited by CAR-T News Motley Fool
Dec-15-17 06:15PM  Bluebird Bio Inc (BLUE) President and CEO Nick Leschly Sold $21.6 million of Shares GuruFocus.com
Dec-13-17 04:09PM  This Biotech Stock Seen As Cheapest Among Rivals In Cancer Drugs Investor's Business Daily
12:31PM  ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More Benzinga
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Davidson DavidChief Medical OfficerJul 11Option Exercise5.503,00016,50127,905Jul 13 04:31 PM
Davidson DavidChief Medical OfficerJul 11Sale180.153,000540,44324,905Jul 13 04:31 PM
Cole JasonChief Legal OfficerJul 09Sale170.255,126872,71517,172Jul 11 04:10 PM
Davidson DavidChief Medical OfficerJul 02Option Exercise5.5010,00055,00434,905Jul 03 04:10 PM
Davidson DavidChief Medical OfficerJul 02Sale153.9610,0001,539,60424,905Jul 03 04:10 PM
Gregory Philip DChief Scientific OfficerJun 18Sale178.413,901695,97825,371Jun 20 04:29 PM
Vachon MarkDirectorJun 14Sale189.991,000189,9920Jun 18 04:43 PM
HIGH SUSANNA GATTIChief Operating OfficerJun 04Option Exercise68.653,500240,27521,000Jun 06 04:36 PM
Davidson DavidChief Medical OfficerJun 04Option Exercise24.4713,000318,11037,905Jun 06 04:39 PM
Vachon MarkDirectorJun 04Option Exercise42.076,000252,4207,000Jun 06 04:42 PM
HIGH SUSANNA GATTIChief Operating OfficerJun 04Sale199.113,500696,89217,500Jun 06 04:36 PM
Davidson DavidChief Medical OfficerJun 04Sale187.8413,0002,441,96524,905Jun 06 04:39 PM
Vachon MarkDirectorJun 04Sale188.226,0001,129,3011,000Jun 06 04:42 PM
Cole JasonChief Legal OfficerMay 04Sale170.893,750640,84922,298May 08 04:18 PM
Davidson DavidChief Medical OfficerMay 02Option Exercise24.4713,000318,11037,905May 04 04:39 PM
Davidson DavidChief Medical OfficerMay 02Sale177.5213,0002,307,69624,905May 04 04:39 PM
Davidson DavidChief Medical OfficerApr 12Option Exercise24.473,00073,41027,905Apr 16 04:48 PM
Davidson DavidChief Medical OfficerApr 12Sale180.173,000540,50824,905Apr 16 04:48 PM
Davidson DavidChief Medical OfficerApr 02Option Exercise24.4722,000538,34046,905Apr 04 04:47 PM
Gregory Philip DChief Scientific OfficerApr 02Option Exercise50.511,25063,13831,522Apr 04 04:50 PM
Gregory Philip DChief Scientific OfficerApr 02Sale168.712,250379,60829,272Apr 04 04:50 PM
Davidson DavidChief Medical OfficerApr 02Sale167.5222,0003,685,38724,905Apr 04 04:47 PM
Vachon MarkDirectorMar 15Option Exercise30.476,000182,8207,000Mar 19 04:06 PM
Vachon MarkDirectorMar 15Sale214.386,0001,286,2501,000Mar 19 04:06 PM
Davidson DavidChief Medical OfficerMar 02Option Exercise5.504,00022,00228,905Mar 06 04:29 PM
Davidson DavidChief Medical OfficerMar 02Sale201.194,000804,75124,905Mar 06 04:29 PM
Gregory Philip DChief Scientific OfficerMar 01Option Exercise50.511,25063,13832,522Mar 05 05:14 PM
Gregory Philip DChief Scientific OfficerMar 01Sale200.002,250449,99530,272Mar 05 05:14 PM
HIGH SUSANNA GATTIChief Operating OfficerFeb 28Option Exercise68.651,04471,67118,544Mar 02 04:01 PM
HIGH SUSANNA GATTIChief Operating OfficerFeb 28Sale202.671,044211,59217,500Mar 02 04:01 PM
Davidson DavidChief Medical OfficerFeb 02Option Exercise5.504,00022,00228,905Feb 05 04:01 PM
Davidson DavidChief Medical OfficerFeb 02Sale202.364,000809,44124,905Feb 05 04:01 PM
Gregory Philip DChief Scientific OfficerFeb 01Option Exercise50.511,25063,13833,522Feb 05 04:02 PM
Gregory Philip DChief Scientific OfficerFeb 01Sale204.902,250461,02031,272Feb 05 04:02 PM
Cole JasonChief Legal OfficerJan 30Option Exercise22.5325,000563,25044,798Feb 01 04:30 PM
HIGH SUSANNA GATTIChief Operating OfficerJan 30Option Exercise68.6514,7941,015,60828,512Feb 01 04:31 PM
HIGH SUSANNA GATTIChief Operating OfficerJan 30Sale195.9117,2623,381,79211,250Feb 01 04:31 PM
Cole JasonChief Legal OfficerJan 30Sale195.9125,0004,897,74319,798Feb 01 04:30 PM
Davidson DavidChief Medical OfficerJan 08Option Exercise5.501,2006,60014,855Jan 09 04:05 PM
Davidson DavidChief Medical OfficerJan 08Sale174.071,200208,88313,655Jan 09 04:05 PM
Gregory Philip DChief Scientific OfficerJan 05Sale173.381,712296,82023,772Jan 09 04:06 PM
Leschly NickPresident and CEOJan 05Sale173.385,435942,298170,297Jan 09 04:06 PM
Walsh Jeffrey T.Chief FinancialJan 05Sale173.383,060530,53024,245Jan 09 04:07 PM
Cole JasonChief Legal OfficerJan 05Sale173.381,129195,74119,798Jan 09 04:05 PM
Davidson DavidChief Medical OfficerJan 05Sale173.382,322402,57913,655Jan 09 04:05 PM
Davidson DavidChief Medical OfficerJan 03Option Exercise5.506,00033,00221,977Jan 05 04:10 PM
Gregory Philip DChief Scientific OfficerJan 03Option Exercise50.511,25063,13827,734Jan 05 04:11 PM
Davidson DavidChief Medical OfficerJan 03Sale180.306,0001,081,78115,977Jan 05 04:10 PM
Gregory Philip DChief Scientific OfficerJan 03Sale180.692,250406,55025,484Jan 05 04:11 PM
Leschly NickPresident and CEODec 13Option Exercise5.5037,873208,317293,232Dec 15 04:09 PM
Leschly NickPresident and CEODec 13Sale184.08117,50021,629,119175,732Dec 15 04:09 PM
Vachon MarkDirectorDec 11Option Exercise30.476,000182,8208,000Dec 13 04:10 PM
Walsh Jeffrey T.Chief FinancialDec 11Option Exercise24.479,900242,25337,205Dec 13 04:09 PM
Walsh Jeffrey T.Chief FinancialDec 11Sale216.549,9002,143,78527,305Dec 13 04:09 PM
Vachon MarkDirectorDec 11Sale216.647,0001,516,4651,000Dec 13 04:10 PM
Gregory Philip DChief Scientific OfficerDec 01Option Exercise50.511,25063,13828,734Dec 05 04:08 PM
Davidson DavidChief Medical OfficerDec 01Option Exercise5.504,00022,00219,977Dec 05 04:08 PM
HIGH SUSANNA GATTIChief Operating OfficerDec 01Sale172.151,282220,69613,718Dec 05 04:09 PM
Davidson DavidChief Medical OfficerDec 01Sale172.424,000689,67915,977Dec 05 04:08 PM
Gregory Philip DChief Scientific OfficerDec 01Sale172.542,250388,21126,484Dec 05 04:08 PM
Walsh Jeffrey T.Chief FinancialNov 10Option Exercise19.999,900197,87037,205Nov 14 04:02 PM
Walsh Jeffrey T.Chief FinancialNov 10Sale149.589,9001,480,86527,305Nov 14 04:02 PM
Gregory Philip DChief Scientific OfficerNov 01Option Exercise50.511,25063,13829,734Nov 03 04:07 PM
Walsh Jeffrey T.Chief FinancialNov 01Option Exercise5.5035,000192,51462,305Nov 03 04:08 PM
Leschly NickPresident and CEONov 01Option Exercise5.502,12711,699257,486Nov 03 04:08 PM
Davidson DavidChief Medical OfficerNov 01Option Exercise5.504,00022,00219,977Nov 03 04:06 PM
Davidson DavidChief Medical OfficerNov 01Sale145.214,000580,82215,977Nov 03 04:06 PM
Leschly NickPresident and CEONov 01Sale145.172,127308,779255,359Nov 03 04:08 PM
Walsh Jeffrey T.Chief FinancialNov 01Sale151.3835,0005,298,32627,305Nov 03 04:08 PM
Gregory Philip DChief Scientific OfficerNov 01Sale144.312,250324,69027,484Nov 03 04:07 PM
Leschly NickPresident and CEOOct 23Sale145.263,700537,455255,359Oct 24 04:17 PM
Leschly NickPresident and CEOOct 20Sale145.023,350485,813259,059Oct 24 04:17 PM
Leschly NickPresident and CEOOct 17Sale145.0510,8231,569,840262,409Oct 19 04:13 PM
Walsh Jeffrey T.Chief FinancialOct 10Option Exercise5.504,90026,95232,205Oct 11 04:37 PM
Walsh Jeffrey T.Chief FinancialOct 10Sale129.944,900636,72427,305Oct 11 04:37 PM
Gregory Philip DChief Scientific OfficerOct 02Option Exercise50.511,25063,13830,734Oct 04 04:02 PM
Davidson DavidChief Medical OfficerOct 02Option Exercise5.504,00022,00219,977Oct 04 04:02 PM
Davidson DavidChief Medical OfficerOct 02Sale131.314,000525,24915,977Oct 04 04:02 PM
Gregory Philip DChief Scientific OfficerOct 02Sale131.822,250296,60228,484Oct 04 04:02 PM
MARAGANORE JOHNDirectorSep 14Option Exercise2.0918,86839,43424,711Sep 18 04:09 PM
MARAGANORE JOHNDirectorSep 14Sale131.2118,8682,475,7335,843Sep 18 04:09 PM
Vachon MarkDirectorSep 12Option Exercise30.476,000182,8208,000Sep 14 04:09 PM
Vachon MarkDirectorSep 12Sale126.826,000760,9232,000Sep 14 04:09 PM
Walsh Jeffrey T.Chief FinancialSep 11Option Exercise5.504,90026,95232,205Sep 13 04:07 PM
Walsh Jeffrey T.Chief FinancialSep 11Sale125.734,900616,06527,305Sep 13 04:07 PM
Leschly NickPresident and CEOSep 01Option Exercise5.506,36435,005295,732Sep 05 04:01 PM
Gregory Philip DChief Scientific OfficerSep 01Option Exercise50.511,25063,13831,734Sep 06 04:06 PM
Davidson DavidChief Medical OfficerSep 01Option Exercise5.5012,00066,00527,977Sep 06 04:06 PM
Davidson DavidChief Medical OfficerSep 01Sale129.0812,0001,548,90415,977Sep 06 04:06 PM
Gregory Philip DChief Scientific OfficerSep 01Sale126.062,250283,63529,484Sep 06 04:06 PM
Leschly NickPresident and CEOSep 01Sale130.0422,5002,925,983273,232Sep 05 04:01 PM
Walsh Jeffrey T.Chief FinancialAug 31Option Exercise5.5012,00066,00539,305Sep 05 04:02 PM
Schenkein David PDirectorAug 31Option Exercise8.162,00016,3125,176Sep 05 04:02 PM
LYNCH DANIELDirectorAug 31Option Exercise5.505002,7503,300Sep 05 04:01 PM
LYNCH DANIELDirectorAug 31Sale120.0050060,0002,800Sep 05 04:01 PM
Schenkein David PDirectorAug 31Sale115.072,000230,1453,176Sep 05 04:02 PM
Walsh Jeffrey T.Chief FinancialAug 31Sale125.0112,0001,500,09127,305Sep 05 04:02 PM
Leschly NickPresident and CEOAug 31Sale115.0924,3332,800,461289,368Sep 05 04:01 PM
Leschly NickPresident and CEOAug 30Sale115.1825,6672,956,307313,701Aug 31 04:16 PM
Walsh Jeffrey T.Chief FinancialAug 28Option Exercise5.501,2506,87628,555Aug 30 04:17 PM